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ABSTRACT

Role of Protein Phosphatase-2A in Regulating Monocyte Activation by Soluble
and Crystalline Uric Acid in Gout
by Sandy ElSayed

Gout is a chronic inflammatory disease caused by the phagocytosis of monosodium urate
monohydrate (MSU) crystals by monocytes/macrophages resulting in downstream expression
and production of interleukin-1 beta (IL-1β) and chemokines. The activation of monocytes by
MSU crystals involves the priming of monocytes with danger signals e.g. lipopolysaccharide
(LPS) or soluble uric acid (UA), crystal phagocytosis and subsequent NLRP3 inflammasome
activation and conversion of pro-IL-1β to active IL-1β. Protein-phosphatase-2A (PP2A) is a
serine/threonine phosphatase that plays an important role in cell growth and inflammation. The
prodrug Fingolimod (FTY720) and its phosphorylated active metabolite (p-FTY720) activate
intracellular PP2A. We hypothesized that monocyte activation by MSU crystals is mediated by a
reduction in intracellular PP2A activity and restoring PP2A activity reduces MSU-induced
inflammation in monocytes. We aimed to investigate the role of PP2A in regulating monocyte
priming and activation by MSU crystals and evaluate whether intracellular PP2A activation
exerts an anti-inflammatory effect in MSU-stimulated monocytes.

Human THP-1 monocytes were primed with a combination of UA and LPS. MSU stimulation
was performed for 4-6 hours and MSU crystal phagocytosis, PP2A activity, IL-1β expression
and production were studied in primed and unprimed monocytes.

We performed PP2A

knockdown in THP-1 monocytes and evaluated the impact of PP2A attenuation on IL-1β
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expression and production in unprimed THP-1 monocytes. Time-dependent intracellular PP2A
activation in response to FTY720 or p-FTY720 treatments was studied and we evaluated the
impact of p-FTY720 treatment on IL-1β expression and production in MSU stimulated human
monocytes.

Priming with UA+LPS increased MSU phagocytosis and IL-1β expression and production in
monocytes. This effect was associated with a reduction in intracellular PP2A activity. PP2A
knockdown increased IL-1β expression and production. FTY720 and p-FTY720 increased
intracellular PP2A activity in monocytes. p-FTY720 treatment reduced IL-1β expression and
production in UA+LPS pre-treated monocytes following MSU stimulation mediated by an
increase in PP2A activity with no alteration in PP2A gene expression.

In summary, UA and LPS enhanced MSU phagocytosis, expression and production of IL-1β via
a reduction in PP2A activity. Pharmacological restoration of PP2A activity exerted an antiinflammatory effect. We conclude that PP2A is a novel therapeutic target for gout treatment.
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1. Introduction
1.1. Background and significance

Gout is a prevalent inflammatory arthritis that affects the articular joints (mainly the
metatarsophalangeal and knee joints) owing to the deposition of insoluble uric acid crystals
in soft tissues causing pain and inflammation (1). In the early history of medical writing, it
appeared in the medical records and constituted a challenge to physicians. Management of
gout symptoms has improved with the availability of anti-inflammatory agents and urate
lowering therapy, but a significant proportion of gout patients still have suboptimal outcomes
(2). The overall prevalence of gout in general population is 1-4% and it is more common in
men (3-6%) than women (1-2%). In populations above 80 years old, the prevalence rises to
10% in men and 6% in woman. Gout affects 2.68 in 1,000 persons annually (3). The
incidence of gout is constantly increasing worldwide and about 3-10% of gout patients are
not adequately managed causing treatment failure gout (refractory gout) which can’t be
controlled by conventional therapies (4,5).

The hallmark of gout is the precipitation of monosodium urate monohydrate (MSU) crystals
contributed to by an increase in serum uric acid levels (1). Gout flares are characterized by
self-limiting acute inflammation that lasts 2-3 days (6) interspersed between the low-grade
inflammatory condition that is chronic gout (7). Hyperuricemia is defined as a uric acid
blood level above 6.5 mg/dL. While hyperuricemia is a risk factor for gout, the relationship
between hyperuricemia and gout is more complex. Many individuals have hyperuricemia
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without gout or even formation of urate crystals while approximately 5% of patients with
hyperuricemia (serum uric acid above 9 mg/dL) advance to gout (8).

Current acute gout treatment modalities include colchicine, corticosteroids and non-steroidal
anti-inflammatory drugs (NSAIDs). Colchicine prevents the activation of macrophages and
subsequently the NLRP3 inflammasome. It also inhibits the production of chemotactic
factors, MCP-1 and IL-8. However, the onset of colchicine’s clinical effect is slow and is
associated with significant toxicities which limits its use in acute flares of gout (9,10). The
most common side effects of colchicine are gastrointestinal symptoms such as diarrhea
reported in 23-77% of patients. Aplastic anemia has also been associated with exposure to
colchicine. The elderly and patients with renal or hepatic dysfunctions are at increased risk
of developing these toxicities. Colchicine has clinically significant drug-drug interactions
with CYP3A4 inhibitors such as erythromycin. NSAIDs are used in acute gout flares owing
to their inhibition of cyclooxygenase-2 (COX-2) and downstream production of
prostaglandins. However, they have a number of side effects. Gastrointestinal side effects
could be minor as dyspepsia or severe as ulcers and perforations occurring in about 10% of
patients. They also reduced kidney function in 1-5% of patients. They are associated with
increased risk of cardiac events especially in patients with cardiovascular diseases. Other
treatments include corticosteroids, which cause dysphoria, mood disorders, hyperglycemia,
immune suppression and fluid retention. This makes the treatment of acute gout in patients
with diabetes and hypertension with glucocorticoids challenging (11). The use of biologics
like IL-1β receptor antagonist is still being evaluated.
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Notably, none of the current

treatments provide a gout cure. Therefore, optimal gout management remains as an unmet
clinical need.
1.2. Gout pathogenesis is a multi-step process initiated by tissue-resident macrophages.
In synovial joints, the synovial membrane is composed of two layers; the first layer is thin
and highly cellular containing synovial macrophages and synovial fibroblasts. Synovial
fibroblasts produce hyaluronic acid and lubricin to establish an extracellular matrix to
support the synovium. Macrophages are low in number in healthy synovial joints. When
hyperuricemia leads to precipitation of MSU crystals in joints, MSU crystals are
phagocytosed by macrophages resulting in the production of proinflammatory cytokines,
which enhances synovial recruitment of additional immune cells leading to inflammation
(12). The effect of precipitated MSU crystals on the macrophages composes the first trigger
of the inflammasome. The cellular recognition of MSU crystals occurs through toll-like
receptors (TLRs), especially TLR2 and TLR4 (13).

This leads to the production and

secretion of pro-inflammatory cytokine, interleukin-1 beta (IL-1β), which recruits more
inflammatory cells and amplifies the inflammatory response (14). MSU crystals mediate
their effect after being phagocytosed by stimulation of nicotinamide adenine dinucleotide
phosphate (NADP) oxidase leading to the generation of reactive oxygen species (ROS) and
activation of nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3)
inflammasome (15).

The innate immune system produces an initial rapid inflammatory response in response to
invading pathogens. This occurs when innate immune receptors recognize pathogen-related
products as an antigen in order to subsequently eliminate those pathogens through their
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engulfment or production of inflammatory cytokines. Innate immune receptors are also
known as pattern recognition receptors (PRRs) and they are present on cell surface and in
cytoplasm. Toll-like receptors (TLRs) are an important group of PRRs. TLRs are located on
immune cells surfaces and play an essential role in mediating the host’s defense against
pathogens. In humans, TLRs are activated by different Pathogen-Associated Molecular
Patterns (PAMPs) including lipopolysaccharide as is the case with TLR4 and lipopeptide
(Pam3CSK4) as is the case with TLR2. TLRs are integral membrane receptors (type 1) with
an N-terminal ligand recognition exterior domain, one transmembrane helix and a C-terminal
cytoplasmic signaling domain also known as toll/interleukin receptor domain figure 1(16).

Figure 1 Structure of toll-like receptors (TLRs). The general structure of TLRs include: 1) An N-terminal
exterior domain for ligand recognition 2) one transmembrane domain 3) A C-terminal intracellular signaling
domain (similar to toll/interleukin domain) (11).

Signaling of TLRs starts with the detection and binding of PAMPs by the extracellular
domain.

When TLR is bound, Myeloid Differentiation 88 (MyD88) recruits IL-1R

associated Kinase Protein (IRAK-1), IRAK-4 and TNF-α Receptor-Associated Factor 6
(TRAF6) to make a receptor complex.

IRAK-1 causes ubiquitination of TRAF6 and
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mediates activation of TGF-β-activated kinase 1 (TAK1)
which is needed for NF-kB and Mitogen-Activated Protein
Kinase (MAPK) activation. Activated TAK1 results in
phosphorylation of IkB Kinase (IKK) and MAPK Kinase 6
resulting in degradation of the NF-kB inhibitor, IkBα. This
leaves NF-kB free to translocate to the nucleus so it can
regulate gene expression. NF-kB is composed of p50 and
p65 subunit proteins, which are held in the cytoplasm by the
inhibitory IkBα subunit. NF-kB is stimulated by many
inflammatory signals including cytokines, MSU crystals and
the inflammatory-stimuli induced phosphorylation-dependent

degradation of IkBα that allows the translocation of NF-kB
to the nucleus to mediate inflammation and decrease
apoptosis. The TLR signaling also includes MAPKs which
are three types: ERK, JNK and p38 which can be activated
separately or together.

ERK and p38 are essential for

production of pro-inflammatory cytokines as TNF-α and IL-1
(figure 2) (17,18). Since phosphorylation is a critical step in
activation of TLR-NF-kB pathway for the activation of NFkB, phagocytosis and recognition of MSU crystals by the

Figure 2 Toll-like Receptor
(TLR) Signaling Pathway.
The signaling pathway is
initiated by binding of
ligands to TLR receptor
resulting in activation of
MyD88 and recruitment of
IRAK and TRAF6 to make
a receptor complex. This
receptor
complex
phosphorylates IKK. IKK
degrades inhibitory IkB
releasing NF-kB. Active
NF-kB is translocated to the
nucleus
causing
transcription
of
proinflammatory cytokines
(17).

TLR receptors leading to pathway protein phosphorylation could be due to the suppression of
the activity of intracellular protein phosphatase 2A (PP2A).

5

Pathogenesis of gout is a two-step process that begins with the NLRP3 inflammasome which is a
multi-protein complex composed of NLR protein, adapter ASC (apoptosis-associated speck-like
protein containing a caspase recruitment domain) and pro-caspase-1. Activation of
inflammasome occurs initially through stimulation of TLR/MyD88 and NF-κB pathway by MSU
crystals leading to transcription of pro-IL-1β gene, while the second step is the assembly of the
multi-protein complex composed of NLR protein, ASC and pro—caspase-1 following activation
by pathogen associated molecular patterns (PAMPs) and/or damage associated molecular
patterns (DAMPs).

Subsequently, caspase-1 cleaves pro-IL-1β to mature IL-1β, which is

biologically active and is released extracellularly. The activation pathway of macrophages by
MSU crystals is shown in figure 3. In addition, MSU cause secretion of ATP and activation of
P2X7 receptor causing efflux of potassium extracellularly which contributes to inflammasome
activation (19). TLR4 plays an important role in gout as IL-1β production decreased significantly
in acute gouty arthritis patients after blockage of the receptor using anti-TLR4 antibody (20).
Priming of the TLR4 receptor may occur through the effect of PAMPs, DAMPs,
lipopolysaccharide (LPS) or uric acid (in soluble or crystalline form).

Uric acid (urate) crystals deposited in the joint cavity are phagocytosed by synovial macrophages
leading to production of pro-inflammatory cytokines such as IL-1ß and TNF-α. While welldifferentiated macrophages can engulf MSU crystals without initiating an inflammatory
response, less-differentiated monocytes produce increased levels of inflammatory cytokines:
IL-1β, TNF-α, IL-6 and IL-8. An acute gout attack is of a self-limiting episode as it resolves
from hours to days after macrophages uptake and remove of crystals hence reducing macrophage
activation and release of chemokines. Furthermore, macrophages remove apoptotic cell bodies,
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produce TGF-β and removes IL-1 to stop inflammation. Terminating acute attack includes
production of anti-inflammatory cytokines, breakdown of pro-inflammatory cytokines, reduction
of expression of receptors of inflammatory cytokines on leukocytes (2,20).

Figure 3 Production of IL-ß following NLRP3 Activation in response to
monosodium urate crystal challenge. The steps of the pathogenesis are
summarized as: 1) Phagocytosis of MSU and stimulation of NADPH oxidase
leading to production of ROS and activation of NLRP3 inflammasome. 2)
Secretion of ATP to interact with purinergic receptor P2X7 on pannexin-1
channels leading to potassium efflux and lower intracellular potassium that can
also lead to NLRP3 activation. 3) Interaction of MSU with TLRs and
activation of MyD88-and NF-κB pathway leading to transcription pro-IL-1β
gene. 4) Finally, caspase-1 cleaves pro-IL-1β to IL-1β, which is released
extracellularly (19).

IL-1 is a large family of cytokines (cell signaling proteins) that play a role in innate immune
responses for defense against pathogens. They increase the expression of adhesion factors on
immune cells to increase their efflux to the site of inflammation. IL-1β is synthesized through
7

NF-kB transcription in the nucleus resulting in the production of the biologically inactive pro-IL1β polypeptide. Post-translational modification by caspase-1 cleaves pro- IL-1β to generate the
mature pro-inflammatory cytokine IL-1β which is released extracellularly to bind to interleukin 1
receptor type 1 (IL-1R1) with the
help of the co-receptor

IL-1

receptor accessory protein (IL1RAP)

to

make

complex.

This

recruitment

of

a

trimeric

results
MyD88,

in
Toll-

interacting protein (TOLLIP) and
IRAK-4. A stable complex is
created between IL-1β, IL-1R1,
IL-1RAP, MyD88 and IRAK-4.
This results in a downstream
cascade of phosphorylation steps

Figure 4 Interleukin-1 beta (IL-1β) signaling pathway. Binding of
IL-1β to its receptor activates the MAPK and ERK pathways
resulting in Iκβ degradation and NF-κB nuclear translocation (17).

which result in NF-kB activation
and release of the transcription factors inducing mRNA expression of hundreds of inflammatory
cytokines including themselves through a positive feedback loop (figure 4) (21,22).

1.3.

The

proinflammatory

mechanism

of

soluble

uric

acid.

Uric acid is recognized as a disease-associated molecular pattern (DAMP) released from dying
cells. The mechanism by which soluble uric acid (UA) causes inflammation is still debatable. In
some perspectives, uric acid acts as an antioxidant. In others, it is a pro-oxidant molecule, which

8

acts as a DAMP on TLRs activating the NF-kB signaling pathway. Also, it reduces the
availability of nitric oxide and increases the production of reactive oxygen species, induces
chemotaxis and stimulates NF-kB and MAPK pathways. Hyperuricemia (without MSU
deposition) was highly associated with disorders such as hypertension and kidney disease which
share the common factor of a ‘redox imbalance’ (16). A popular theory posits that UA causes
state changes in cellular redox and increases the production of ROS leading to NLRP3 activation
and eventually production of IL-1β. In one study, UA was also found to be responsible for
increasing the production of IL-1β through the NLRP3 and MyD88 pathways (18). In that study,
bone marrow derived macrophages were incubated in the presence of UA alone or in
combination with LPS for 24 hours. It was observed that the UA+LPS treatment induced higher
IL-1β expression compared to control cells and cells stimulated with UA or LPS alone (23).

1.4. Protein phosphatase-2A (PP2A) plays a key role in regulating intracellular
inflammatory signaling pathways.
In cells, one third of proteins’ functions are regulated by phosphorylation and that leads to
control of various cell functions. Based upon the physiological requirements of the cell, proteins
shift between phosphorylated and dephosphorylated states using protein kinases and
phosphatases (24). The family of protein phosphatases is divided mainly into two groups named
as protein serine/threonine phosphatases (PSPs) and phosphotyrosine phosphatase (PTPs). PSPs
include protein phosphatase-1 (PP1) and protein phosphatase 2A (PP2A) (25,26). PP2A was
found to be involved in critical processes regarding cellular growth, cell cycle, DNA replication,
transcription and translation, cell proliferation, apoptosis, signal transduction, cell mobility and
cytoskeleton dynamics which made it a major target for therapy in cancer, heart,
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neurodegenerative diseases and diabetes research (25,26). PP2A is a complex composed of three
subunits: scaffold subunit (A), catalytic subunit (C) which can exist independently forming an
active core dimer and a variable regulatory subunit (B) making a heterotrimer complex (27).
Activation of PP2A leads to initiation of multiple signaling pathways leading to apoptosis in
cancer, modulation of cell growth and survival. (figure 5) (28). One study found that serum
levels of proinflammatory cytokines TNF-α and IL-6 increased in PP2A knock out mice
following challenge with LPS (29). This was associated with increased phosphorylation in the
MAPK pathways and the NF-κB pathway in bone marrow derived macrophages from knock out
mice. Authors concluded that PP2A played an essential role in regulation of inflammation in the
site of a septic insult through its targeting of MyD88 and Toll/IL-1R domain-containing adaptor
(29). Taken all evidence together, it is plausible to expect that activation of PP2A could
lead to reduction of inflammation in gout.

Figure 5 Regulation of protein phosphatase-2A (PP2A) and its associated signaling pathways. PP2A is composed
of three subunits: structural, regulatory and catalytic. PP2A regulates multiple pathways including p53, Wnt and
AKT pathways (28).
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1.5. Clinically-available PP2A activators show efficacy in models of inflammation.
Fingolimod (FTY720) is an oral treatment for
multiple sclerosis. Fingolimod is a prodrug that is
converted to the active metabolite Fingolimod
phosphate (FTY720-P) by the enzyme sphinogsine
kinase (figure 6). FTY720-P looks like the natural
ligand sphingosine-1-phosphate (S1P), which is a
lipid mediator present extracellularly to S1P

Figure 6 Phosphorylation of Fingolimod
(FTY720) to Fingolimod phosphate (FTY720-P)
and interaction with the S1P1 receptor.

cognate G protein-coupled receptors. S1P subtype
1 (S1P1) regulates the lymphocytes migration to
circulation from lymphoid tissues and hence plays a
major role in immunity. When FTY720-P binds to
S1P1 with high affinity, it induces the persistent
internalization of the receptor and thus antagonizes
S1P-driven

migration

of

lymphocytes

from

lymphoid tissues. (30). FTY720 was found to block

Figure 7 Activation of protein-phosphatse-2A by
fingolimod (FTY720) via inhibition of SET
protein (30).

the PP2A inhibitor protein SET and thereby
enhancing the activity of PP2A figure 7 (31,32). In one study, activation of PP2A with FTY720
(2.5 µM) has either limited or prevented tissue injury and inflammation in injury models of acute
respiratory distress syndrome (ARDS) leading to decreased production of the chemokine
interleukin-8 (IL-8) (33,34). Therefore, FTY720-P can be used as a research tool to examine
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whether activating PP2A leads to decreased inflammation in gout as illustrated by decreased
production of IL-1β by MSU challenged monocytes/macrophages (35).

2. Hypothesis
UA and LPS prime peripheral blood monocytes resulting in enhancement of MSU crystal
phagocytosis and downstream production of inflammatory cytokines and PP2A is a critical
regulator of this priming effect.
2.1. Aim 1:
To examine the activating effect of UA and LPS on MSU crystal phagocytosis and downstream
activation of NLRP3 inflammasome, NF-κB and IL-1β expression and production in THP-1
monocytes and test whether this effect is associated with a reduction in intracellular PP2A
activity.

2.2. Aim 2:
To study the role of PP2A in regulating crystal-induced inflammation in monocytes and evaluate
the utility of a PP2A-activating drug, fingolimod phosphate (FTY720-P), in providing an antiinflammatory activity in MSU stimulated monocytes.
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3. Materials and Methods
Human monocytes (THP-1)
Human monocyte cells (THP-1, ATCC, USA) were cultured in 10% FBS, 1%
penicillin/streptomycin

RPMI-1640

media

and

2-Mercaptoethanol

as

per

ATCC

recommendation in T75 flask to a density of 1.5 × 106 cells/mL in 37°C and 5% CO2.

3.1. Reagents
Monosodium urate monohydrate (MSU) crystals
Pyrogen-free MSU crystals (Invivogen, USA) were resuspended with sterile phosphate buffered
saline (PBS) and maintained at 4oC.

Fingolimod hydrochloride (FTY720)
Fingolimod hydrochloride (5 mg; Cayman Chemical; catalog # 10006292, USA) were
reconstituted with 1,000µL dimethyl sulfoxide (DMSO) to make a stock solution (14.5 mM) and
stored at -20°C. At the time of experiment, an intermediate concentration of 500µM was made
by adding 34.5µL from the stock solution to 965.5µL DMSO. Subsequently, 5µL from the
intermediate stock solution were added to each 1,000µl media in wells to make final
concentration of fingolimod 2.5µM.

Fingolimod phosphate (FTY720-P)
Fingolimod phosphate (0.59 mg; Cayman Chemical; catalog # 10008639, USA) was
reconstituted with 10mL dimethyl sulfoxide (DMSO) to make a stock concentration (152.2µM)
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and stored at -20°C. To make a final concentration of 2.5µM, 16µL of reconstituted solution
were added to each 1,000µL media in well.

Uric Acid (UA)
Uric acid (U2625-25G, Sigma-Aldrich, USA) was solubilized as a concentration of 50 mg/dL in
warm serum-free RPMI 1640 media.

3.2. Phagocytosis of FITC labeled fluorescent beads in primed monocytes
Monocytes were seeded in 24-well plate (0.6x106 cells/well) and were primed using 50mg/dL
uric acid and 10ng/ml LPS for 24 hours (36). Latex beads-rabbit IgG-FITC complex (7.5µl/well;
Phagocytosis Assay Kit, Cayman Chemicals) were added directly into respective wells and
incubated for 4 hours at 37°C. Our experimental groups included: control unprimed monocytes
(± latex beads), and UA, LPS, UA and LPS-primed monocytes (+ latex beads). To assess
phagocytosis, cells were centrifuged for five minutes at 400xg, then they were resuspended in
300µL assay buffer. The proportion of monocytes that phagocytized fluorescent beads was
assessed based on increased side scatter properties using BD FACSVerse Flow Cytometer.

3.3. Phagocytosis of MSU crystals by primed monocytes
Monocytes were seeded in 6-well plate (0.5x106 cells/well) as control (± MSU), and UA, LPS,
UA and LPS (+ MSU). Cells were primed using 50mg/dL uric acid and 10ng/ml LPS for 24
hours (36). This was followed by 4 hours treatment with MSU crystals (100µg/mL). Cells were
collected, centrifuged for 3,000 rpm for five minutes. The supernatant was discarded and cells
were suspended in 300µL PBS. Indirect assessment of MSU phagocytosis was determined by
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analyzing the change in cell side-scatter distribution due to crystal phagocytosis using a flow
cytometer (BD FACSVerse).

Two regions of interest were identified; P1 representing the

monocyte population in the absence of MSU exposure and P2 representing the monocyte
population with increased side scatter due to MSU phagocytosis. MSU-positive cells were
calculated as the ratio of cells in the P2 region to the sum of cells in the P1 and P2 regions.

3.4. IL-1β gene expression in primed monocytes
A total of 500,000 monocytes were plated per well in a 6-well plate. Cells were primed with UA
and LPS for 24 hours at 37°C as described above. Cells were treated with MSU crystals
(100µg/mL) for 6 hours. After incubation, cells were collected, centrifuged at 3,000 rpm for 5
minutes to be pelleted. The supernatant was collected and stored at -20°C while total RNA was
extracted using trizol reagent (Thermo Fisher Scientific, USA) and mRNA concentrations were
determined using Nanodrop One Microvolume UV-Vis spectrophotometer (Thermo Scientific,
USA). cDNA was synthesized using iScriptTM cDNA Synthesis Kit (Biorad, USA). qRT-PCR
was done by QuantstudioTM 3 Real-Time PCR System (Thermo Fisher Scientific, USA) with
TaqMan® Fast Advanced Master Mix (Life Technologies, USA). The probes were labeled with
6-carboxyfluorescein (6-FAM). The primers used in PCR are listed in Table 1. The cycle
threshold (Ct) values of the gene of interest were normalized with the value of GAPDH of the
same sample, and the relative expression of each gene was analyzed using the 2-ΔΔCt method (37).
Gene

Forward (5’ to 3’)

Reverse (5’ to 3’)

GAPDH

ACTGGCGTCTTCACCACCAT

AAGGCCATGCCAGTGAGCTT

IL-1β

TTGTTGCTCCATATCCTGTCC

CACATGGGATAACGAGGCTT

PP2Ac

TCGTTGTGGTAACCAAGCTG

AACATGTGGCTCGCCTCTAC

Table 1 Primers used for gene amplification
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3.5. IL-1β production by primed THP-1 monocytes
Monocytes (500,000 cells per well) were seeded in 6-well plates and primed with UA and LPS
for 24 hours as described above. Then, they were stimulated with MSU (100 μg/mL) for 6 hours.
Media supernatants were collected and IL-1β concentration was measured using Human IL1beta/IL-1F2 Duoset ELISA kit (R&D Systems; DY201-05, USA).

3.6. PP2A knockdown using protein phosphatase-2A catalytic subunit (PP2Ac) siRNA
Monocytes (1.0x10-6 cells/well) were seeded in 6 well plates using Opti-MEMTM Reduced
Serum Medium (Thermo Fisher; 31985088, USA) and labeled as control, PP2A siRNA and
negative control. PP2CA siRNA (Thermo fisher Scientific; AM16708, USA) and SilencerTM
Negative Control siRNA (Thermo fisher Scientific; AM4611, USA) were reconstituted and
added to their respective wells at concentration of 3μM with 9μl of LipofectamineTM 3000
Transfection Reagent (Invitrogen; L3000001, USA) in a total volume of 2500μl/well and
transfection was left for 24 hours at 37oC. PP2A knockdown was confirmed using gene
expression. First, total RNA was extracted using trizol reagent (Thermo Fisher Scientific, USA)
and mRNA concentrations were determined using Nanodrop One Microvolume UV-Vis
spectrophotometer (Thermo Scientific, USA).

cDNA synthesis and qPCR assays were

performed as described above. The probes were labeled with 6-carboxyfluorescein (6-FAM).
The primers used in PCR are listed in Table 1. The cycle threshold (Ct) values of the gene of
interest were normalized with the value of GAPDH of the same sample, and the relative
expression of each gene was analyzed using the 2-ΔΔCt method. The relationship between PP2A
expression and PP2A activity was established by measuring PP2A activity following PP2A
knockdown. After 24 transfecting THP-1 cells for 24 hours, transfected cells were collected,
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centrifuged at 3,000 rpm for five minutes, pelleted and lysed using RIPA Buffer with protease
inhibitor and then re-centrifuged at 14,000 rpm for ten minutes. The protein isolate was collected
and stored at -80°C. Protein levels were measured using Pierce™ BCA Protein Assay Kit
(Thermo Fisher Scientific; 23225, USA). A total of 5 μL of each sample was mixed with 195μL
RIPA buffer and protease inhibitor in microcentrifuge tubes then 75μL were added in 96-well
plates in duplicate wells. Working reagent (75μl) were added to each well and mixed on shaker
for 30 seconds then plate was covered and incubated at 37°C for 30 minutes. Absorbance was
measured at 562nm. After determining protein levels, 5μg/well protein was used to measure
PP2A activity using the PP2A immunoprecipitation kit (Sigma Aldrich, USA). Protein samples
were added to 4μL anti-PP2A C subunit and 30μL protein A agarose slurry then the volume was
brought to 120μL with the assay buffer. Samples were incubated on shaker for 3 hours at 4°C.
Agarose beads were then washed 3 times with 400μL 1X TBS and once with 200μl assay buffer.
A phosphopeptide substrate (40μL) were added to the beads and 20μL assay buffer. The mixture
was incubated for ten minutes at 30°C on a shaking incubator then centrifuged and 25μL of
supernatants were added to each well in 96-well plate in duplicates. For color development,
100μL of malachite green phosphate detection solution were added to each well. Absorbance
was measured at 650nm.

3.7. IL-1β expression and production in PP2Ac siRNA-treated THP-1 monocytes following
incubation with MSU crystals
Monocytes (1.0x10-6 cells/well) were seeded in 6 well plates using Opti-MEMTM Reduced
Serum Medium (Thermo Fisher; 31985088, USA) and labeled as control (±MSU), PP2A siRNA
and negative control (+MSU). PP2CA siRNA (Thermo fisher Scientific; AM16708, USA) and
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SilencerTM Negative Control siRNA (Thermo fisher Scientific; AM4611, USA) were
reconstituted and added to their respective wells at concentration of 3μM with 9μL of
LipofectamineTM 3000 Transfection Reagent (Invitrogen; L3000001, USA) in a total volume of
2,500μL/well and transfection was left for 24 hours at 37oC. MSU crystals (100μg/mL) were
then added to their respective wells. Cells were collected, centrifuged, pelleted and media
supernatants were collected and IL-1β gene expression and media concentrations were
determined as described above.

3.8. Impact of FTY720 and FTY720-P treatments on intracellular PP2A activity in human
THP-1 monocytes
THP-1 monocytes (0.4x106 cells per well) were seeded in 6 well plates. FTY720 (2.5μM) and
FTY720-P (2.5μM) were added and cells were collected at 1 hour, 3 hours, 6 hours and 24 hours.
PP2A immunoprecipitation and PP2A activities were determined as described above.

3.9. Impact of FTY720-P treatment on IL-1β and PP2A expression and IL-1β production in
MSU-treated primed THP-1 macrophages
A total of 500,000 THP-1 monocytes were plated per well in 6-well plates. Monocytes were
primed with UA and LPS for 24 hours at 37°C as described above. Cells were treated with MSU
crystals (100μg/mL) for 6 hours with and without pre-incubation with FTY720-P (3 hours;
2.5μM). After incubation, cells were collected, centrifuged at 3,000 rpm for 5 minutes to be
pelleted. Supernatants were collected and stored at -20°C. RNA isolation, cDNA synthesis and
qPCR were performed as described above. Genes of interest included PP2Ac and IL-1β using
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GAPDH as a reference gene. IL-1β levels in media supernatants were quantified as described
above.

3.10. Impact of FTY-720-P on THP-1 cell viability
To rule out the possibility that FTY720-P’s effect is due to a cytotoxic effect on THP-1
monocytes, monocytes (25,000/well) were seeded in 96-well plate in 100μL per well in triplicate
wells as the following groups: background (100μL culture medium), low background (100μL
culture medium and monocytes), positive control (100μL culture medium and monocytes with 10
μL Cell Lysis Solution), experimental groups including MSU± FTY720-P and MSU (UA+LPS)±
FTY720-P. Priming was done with UA and LPS as described above for 24 hours.

Cell

cytotoxicity was determined using lactate dehydrogenase (LDH) Assay Kit (Abcam; ab65393,
USA). Cells were pre-incubated with FTY720-P for 3 hours then treated with MSU crystals for
6 hours. Then cell lysis solution was added to positive control and incubated for ten minutes. The
microtiter plate was centrifuged at 600xg for ten minutes then clear medium solution (10μL/well)
was transferred into optically clear 96-well plate. The LDH reaction mix (100μL/well) was
added to quantify the release of intracellular LDH, which occurs upon damage to cell membrane.
Absorbance of all controls and samples was at 450nm and the formula used to calculate percent
cell cytotoxicity was: Cytotoxicity (%) = ((Test Sample – Low Control)/ (High Control – Low
Control))*100.

3.11. Statistical Analyses
Statistical analyses of gene expression data were performed using ΔCt values (Ct target gene-Ct
GAPDH) for each gene of interest in each experimental group. Continuous variables were
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initially evaluated whether they satisfied the requirements for parametric statistical tests.
Statistical significance comparing two groups or multiple groups with parametric data was
assessed by Student’s t test or ANOVA followed by post-hoc multiple comparisons using
Tukey’s post-hoc test. Statistical significance comparing two groups or multiple groups with
nonparametric data was assessed by Rank Sum test or ANOVA on the ranks. A p value of <
0.05 was considered statistically significant. Data are presented as scatter plots with mean and
standard deviations highlighted. Data were generated from at least 3 independent experiments
with duplicate wells per treatment.

4. Results
4.1. Impact of UA+LPS priming on phagocytosis of fluorescent beads and MSU crystals by
THP-1 monocytes
Using the fluorescent beads phagocytosis assay, we observed that priming with LPS alone or
LPS + UA increased bead
phagocytosis
monocytes.

by

THP-1

Representative

flow cytometry plots depict
increased shift of fluorescently
labeled cell population in LPStreated and LPS + UA-treated
THP-1 monocytes compared to
control unprimed cells (figure

Figure 8 Impact of soluble uric acid and lipopolysaccharide
priming on phagocytosis of FIT-C labeled beads by THP-1
monocytes. A) Representative flow cytometry scatter plots
showing enhanced latex beads phagocytosis (as shown by more
cells with increased side scatter in P2 region of interest) by THP-1
monocytes. B) Quantitative determination of beads phagocytosis
using % positive cells in P2 region of interest. Priming of
monocytes with LPS and UA significantly increased beads
phagocytosis by THP-1 monocytes. *p<0.001, **p<0.01.
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8A). The enhancement in cell phagocytic behavior appeared to be due to LPS priming as
phagocytosis of beads by UA-primed monocytes was not different (p>0.05) from beads’
phagocytosis by control cells (figure 8B). On the other hand, LPS alone or LPS + UAprimed monocytes exhibited significantly higher (p<0.001) phagocytic activity against
fluorescent beads compared to control untreated monocytes (figure 8B).

Representative flow cytometry plots of MSU phagocytosis by THP-1 monocytes under
control and UA and LPS priming conditions are presented in figure 9A. UA and LPS
priming appeared to enhance MSU phagocytosis by THP-1 monocytes as illustrated by an
increase in the percentage of THP-1 monocytes in the P2 region of interest compared to
control unprimed monocytes. THP-1 monocytes did not exhibit a significant ability to
phagocytose MSU crystals (p>0.05) (figure 9B). However, UA and LPS priming increased
MSU phagocytosis by THP-1 monocytes compared to unprimed monocytes (p<0.001;
p<0.01 respectively). A combination of UA + LPS priming increased MSU phagocytosis by
THP-1 monocytes and that effect was not significantly different from UA priming alone.

Figure 9 Impact of soluble uric acid and
lipopolysaccharide priming on phagocytosis
of monosodium urate (MSU) crystals by
THP-1 monocytes. A) Representative flow
cytometry scatter plots showing enhanced
MSU crystal phagocytosis (as shown by
more cells with increased side scatter in P2
region of interest) by THP-1 monocytes. B)
Quantitative
determination
of
MSU
phagocytosis using % positive cells in P2
region of interest. Priming of monocytes with
LPS and UA significantly increased MSU
phagocytosis
by
THP-1
monocytes.
*p<0.001, **p<0.01.
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4.2. Impact of UA + LPS priming on intracellular PP2A activity, IL-1β expression and
production

Following priming with UA and LPS and subsequent treatment with MSU crystals for 6
hours, PP2A activity was significantly lower compared to UA+LPS (p<0.05) (figure 10A).
In contrast, UA + LPS priming did not alter intracellular PP2A activity compared to control
monocytes (p<0.05). UA + LPS priming significantly increased IL-1β expression and
production in MSU stimulated monocytes (p<0.001 for both comparisons) (figure 10B &
10C respectively).

Figure 10 Impact of uric acid (UA) and lipopolysaccharide (LPS) priming on protein phoaphstase-2A (PP2A)
activity, interleukin-1 beta (IL-1β) expression and production in THP-1 monocytes. A) MSU challenge in
UA+LPS primed monocytes resulted in a significant reduction in PP2A activity as measured by ability to
generate phosphate from a phosphorylated peptide substrate. B) IL-1β expression in THP-1 monocytes
following priming with UA or LPS and MSU challenge for 6 hours. C) IL-1β production in THP-1 monocytes
following priming with UA or LPS and MSU challenge for 6 hours. A combination of LPS and UA priming
resulted
in
a
significant
increase
in
IL-1β
expression
and
production.
*p<0.001, **p<0.01, n.s. non-significant.
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4.3. PP2A knockdown using PP2A siRNA and effect of knockdown on IL-1beta
expression and production
PP2A knockdown using PP2A siRNA for 24 hours resulted in a significant reduction in
PP2A expression (figure 11A) compared to scramble siRNA (p<0.001). The magnitude of
reduction in PP2A expression was approximately 60%. PP2A activity following PP2A
siRNA treatment showed significantly lower PP2A activity in knockdown cells compared to
control and scramble siRNA (figure 11B). In PP2A-knockdown monocytes, MSU treatment
resulted in a significant increase in IL-1β expression and production compared to untreated
and scramble siRNA-treated THP-1 monocytes (p<0.05 for both comparisons) (figure 11C &
11D).

Figure 11 Impact of protein phosphatase-2A (PP2A) silencing on monosodium urate monohydrate (MSU)
crystal -induced interleukin-1 beta (IL-1β) expression and production by human THP-1 monocytes.
A) PP2Ac expression in THP-1 monocytes after PP2A siRNA knockdown. B) PP2A activity in THP-1
monocytes following PP2A siRNA knockdown. PP2A knockdown resulted in a reduction in PP2A activity. C)
IL-1β expression in THP-1 monocytes following PP2A knockdown and MSU challenge for 6 hours. D) IL-1β
production in THP-1 monocytes following PP2A knockdown and MSU challenge. PP2A knockdown enhanced
IL-1beta expression and production in comparison to control and scramble stimulated with MSU crystals.
*p<0.001, **p<0.01, n.s. non-significant.
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4.4. PP2A activation by FTY720 and FTY720-P at different time-points and FTY720-P
enhancement of PP2A activity of primed monocytes
The PP2A activity was determined at 1, 3, 6 and 24 following incubation with prodrug
FTY720 or active metabolite FTY720-P (figure 12A and 12B).

The peak activity for

prodrug was at 6 hours incubation while peak activity of the active metabolite was at 3 hours
after addition to monocytes (figure 12A and 12B). Priming of monocytes using UA and LPS
resulted in significantly reduced PP2A activity compared to control (p<0.01) and this
reduction was reversed by the addition of PP2A activating drug FTY720-P (p<0.05) (figure
12C).

Figure 12 Impact of fingolimod prodrug (FTY720) and active phosphate metabolite (FTY720-P) treatments on
intracellular protein phosphatase-2A (PP2A) activity in THP-1 monocytes. A) PP2A activity in FTY-720treated monocytes. B) PP2A activity in FTY720-P-treated monocytes. The highest activity of FTY720 was at 6
hours while FTY720-P had peak activity after 3 hours. C) PP2A activity in THP-1 monocytes following
priming with UA or LPS and challenge with MSU ± FTY720-P pre-incubation for 3 hours. The significant
reduction in PP2A activity in primed monocytes was reversed by the addition of FTY720-P. PP2A activity was
determined by its ability to generate phosphate from a phosphorylated peptide substrate. *p<0.001, **p<0.01;
***p<0.05.
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4.5. Impact of FTY720-P on cell viability, PP2A expression, IL-1β expression and
production in human THP-1 monocytes
The impact of FTY720-P treatment on THP-1 monocyte viability, PP2Ac expression and IL-1β
expression and production in UA + LPS primed and MSU treated THP-1 monocytes are
presented in figure 13. There was no significant increase in cell cytotoxicity as a result of
FTY720-P treatment (figure 13A) and FTY720-P treatment did not change the gene expression
level of PP2Ac (figure 13B).

In contrast, FTY720-P treatment reduced IL-1β expression

(p<0.001) (figure 13C) and mature IL-1β production (p<0.001) (figure 13D) in UA+LPS pretreated human monocytes following MSU stimulation.

Figure 13 Impact of fingolimod phosphate (FTY720-P) treatment on THP-1 monocyte viability, expression of
PP2Ac, IL-1β expression and production in UA + LPS primed and MSU stimulated monocytes. *p<0.001;
**p<0.01. A) FTY720-P treatment did not display significant cell toxicity. B) FTY720-P treatment did not
alter PP2Ac gene expression. C) FTY720-P treatment reduced IL-1β gene expression. D) FTY720-P treatment
reduced IL-1β production.
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5. Discussion
Gout is a chronic inflammatory disease which had been long associated with hyperuricemia (38).
In hyperuricemia, MSU crystals are precipitated in articular joints, and are recognized by TLRs
and subsequently activate the MyD88 NLRP3 pathway releasing caspase-1. Moreover, MSU
crystals act on NF-kB pathway causing the transcription of the pro-inflammatory cytokine proIL-1β which is cleaved by caspase-1 to IL-1β that is released from immune cells via exocytosis
(39). LPS plays an important role in inflammation through its agonistic activity on TLR4
receptor stimulating the NLRP3 pathway (40). The role of hyperuricemia as an inflammatory
signal had been controversial. A study had shown that uric acid has a dual role as anti-oxidant
and pro-oxidant (41).

On the other hand, other studies associated hyperuricemia with co-

morbidities involving oxidative stress suggesting that the inflammatory mechanism of
hyperuricemia is caused by redox imbalance (42) or stimulation of TLR. Current available
treatments for gout include colchicine, NSAIDs, corticosteroids and IL-1b receptor antagonists
and despite their different modes of action, they all had serious adverse effects with no
remarkable efficiency (43). Therefore, gout remains a research area of interest.

Protein phosphatase-2A (PP2A) is a heterotrimeric enzyme, which plays an important role in
intracellular inflammatory pathways through its dephosphorylating key proteins in cell signaling
cascades. Although it was studied intensively for its role in cancer as a potential therapeutic
target (44), some emerging studies focused on its potential anti-inflammatory role via reducing
the production of pro-inflammatory cytokines TNF-alpha and IL-6 following TLR4 agonistic
activity by LPS (30). The activity of PP2A is regulated through the inhibitory enzyme SET
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which is bound to the catalytic subunit of PP2A preventing it from interacting with other
intracellular components (45).

The most popular PP2A activating drug (PAD) is fingolimod (FTY720) which is present in two
forms including: fingolimod hydrochloride prodrug (FTY720) and its active metabolite
following intracellular phosphorylation by sphingosine kinase-2; fingolimod phosphate
(FTY720-P). FTY720-P binds to SET releasing PP2A therefore rendering it active. Recent
studies focused on FTY720-P’s potential anti-inflammatory role by reducing release of IL-8
(35). In our study, we investigated the priming role of UA and LPS on THP-1 monocytes
through MSU phagocytosis and subsequent activation of NF-kB and NLRP3 pathways resulting
in expression and production of pro-inflammatory cytokine IL-1b and associating this with the
reduction in PP2A activity. In addition, FTY720-P was used as a PAD to enhance PP2A activity
and investigate whether PP2A activation produced an anti-inflammatory effect in our crystalinduced inflammation in vitro model.

We found that UA and LPS primed monocytes and enhanced phagocytosis of MSU crystals.
Phagocytic activation of monocytes was confirmed using fluorescent FIT-C labeled latex beads.
The priming of UA and LPS also enhanced phagocytosis of beads compared to control.
However, unlike MSU crystals, higher bead phagocytosis was seen with LPS alone compared to
UA alone. This could be due to the higher precipitation of MSU crystals with UA due to similar
chemical composition, which didn’t happen with the beads. In both cases, the dual activating
effect

of

UA

and

LPS

surpassed

either

of

them

alone.

Priming corresponded with higher expression and production of the pro-inflammatory cytokine
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IL-1b following MSU phagocytosis. This could be due to the stimulation of NLRP3 and NF-kB
pathways. Intracellular PP2A activity was not found to decrease with priming alone but after the
phagocytosis of MSU crystals.

This might be due to the dual signaling needed by the

inflammatory pathway through both NLRP3 and NF-kB.

The association of enhanced

expression and production of IL-1b with a decrease in PP2A activity suggests that PP2A plays a
role in in inflammation. The role of PP2A was further investigated by knocking down PP2Ac
gene using PP2Ac siRNA. PP2A expression decreased with PP2A knockdown and this was
associated with a decrease in PP2A activity. In unprimed monocytes after PP2A knockdown and
MSU challenge, there was higher expression of IL-1b compared to control monocytes as well as
enhanced IL-1b production. This confirms the previous association between the decrease of
PP2A activity and increased severity of inflammation.

We further compared PP2A activation in THP-1 monocytes using the FTY720 prodrug and the
active metabolite FTY720-P at different time points.

The peak activity for FTY720 was

observed at 6 hours while the peak activity for FTY720-P occurred at 1 hour. This is attributed
to the metabolism of FTY720 since it takes about 6 hours to get uptaken into monocytes and
phosphorylated by the intracellular sphingosine kinase-2 into FTY720-P, the active form of the
drug. In case of FTY720-P, the addition of the active metabolite resulted in a quicker effect on
PP2A activity. FTY720-P was therefore used as our PP2A activating drug in follow-up studies.
In monocytes primed with UA and LPS, the decreased PP2A activity was reversed by the preincubation of cells with FTY720-P for 3 hours prior to MSU challenge affirming the PP2A
restoring activity of FTY720 especially with primed monocytes.

Furthermore, in primed

monocytes, the higher expression and release of IL-1b was reversed by pre-incubation with
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FTY720-P. This confirms the anti-inflammatory role of FTY720-P through its action as a PP2A
activating drug. Interestingly, PP2A activation was not due to an increased PP2A intracellular
pool as FTY720-P treatment showed no significant effect on PP2A expression in primed cells
compared to control. Finally, LDH cytotoxicity assay showed no significant cellular death
confirming that all results aren’t caused by cellular death due to priming or due to addition of
FTY720-P.

6. Conclusions
We conclude that priming THP-1 monocytes using UA and LPS results in higher MSU
phagocytosis and subsequently higher expression and production of IL-1b with decreased PP2A
activity. Increasing PP2A activity through PADs as FTY720-P can reverse the pro-inflammatory
effect of priming. PP2A is a novel target in gout.
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